Drug Approval | March 27, 2024
             
           FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
 
        Subscribe To Our Newsletter & Stay Updated